TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18569264

Group type: EXPERIMENTAL
Intervention: dechloro ethylcloprostenolamide (Group A: 1.69 mm)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: dechloro ethylcloprostenolamide (Group B: 1.94 mm)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: dechloro ethylcloprostenolamide (Group D: 1.44 mm)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (Group C: 0.63 mm)
Number of subjects: 34
Study: 18554862

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (200 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol (2 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of soy isoflavones and 17-beta-estradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy isoflavones tested directly and indirectly (metabolized)
Number of subjects: 0
Study: 15050262

Group type: EXPERIMENTAL
Intervention: Handheld keratometry with subjects in lying posture and with artificial tears
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Handheld keratometry with subjects in sitting posture and with artificial tears
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Handheld keratometry with subjects in lying posture without artificial tears
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Handheld keratometry with subjects in sitting posture without artificial tears
Number of subjects: 35

Group type: COMPARATOR
Intervention: Topographic keratometry
Number of subjects: 35
Study: 10790463

Group type: EXPERIMENTAL
Intervention: Home visits by nurses
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Pediatric clinic visits by nurse practitioners or physicians
Number of subjects: 1163
Study: 9348446

Group type: EXPERIMENTAL
Intervention: Proclear lens
Number of subjects: 42

Group type: COMPARATOR
Intervention: Permaflex lens
Number of subjects: 42
Study: 8244135

Group type: EXPERIMENTAL
Intervention: 100 mg gliadin (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 mg gliadin (group B)
Number of subjects: 20
Study: 3513568

Group type: EXPERIMENTAL
Intervention: High-dose folic acid (250 mg per day for 3 months)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-dose folic acid (250 mg per day for an additional 3 months)
Number of subjects: 5
Study: 31916605

Group type: EXPERIMENTAL
Intervention: Transcystic biliary drainage
Number of subjects: 310

Group type: COMPARATOR
Intervention: No transcystic drainage (control)
Number of subjects: 310
Study: 31304600

Group type: EXPERIMENTAL
Intervention: Single dose regimen (1500 IU anti-D at 28 weeks)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Two-dose regimen (625 IU anti-D at 28 and 34 weeks)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Single dose regimen
Number of subjects: 277

Group type: COMPARATOR
Intervention: Two-dose regimen
Number of subjects: 277
Study: 29849845

Group type: EXPERIMENTAL
Intervention: Crushed intranasal Morphine ARER
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intact oral Morphine ARER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crushed intranasal ER morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intact oral Morphine ARER and crushed intranasal Morphine ARER
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine ARER
Number of subjects: 0
Study: 27776098

Group type: EXPERIMENTAL
Intervention: Adductor canal blockade with 10 mL of bupivacaine 0.25% with epinephrine 1:300,000
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline adductor canal block
Number of subjects: 40
Study: 24370568

Group type: EXPERIMENTAL
Intervention: 100% oxygen at 1.5 ATA (1.5 ATAO2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100% oxygen at 2.0 ATA (2.0 ATAO2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham Air
Number of subjects: 60
Study: 22371239

Group type: EXPERIMENTAL
Intervention: BoNT-A (Dysport) 500 U
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 19786514

Group type: EXPERIMENTAL
Intervention: Home visit intervention program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard health care
Number of subjects: 90
Study: 17259258

Group type: EXPERIMENTAL
Intervention: Warm water and pulsating negative pressure treatment (NM group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Forced-air warming (SM group)
Number of subjects: 20
Study: 15081453

Group type: EXPERIMENTAL
Intervention: Novel fatty acid supplement
Number of subjects: 0
Study: 11167480

Group type: EXPERIMENTAL
Intervention: Intravenous Buscopan 20 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 44
Study: 9571344

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LIS) injected 20 min before the meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LIS) injected immediately before the meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LIS) injected 15 min after the meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular human insulin (REG) injected 40 min before the meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular human insulin (REG) injected 20 min before the meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular human insulin (REG) injected immediately before the meal
Number of subjects: 18
Study: 7831946

Group type: EXPERIMENTAL
Intervention: Rapid Infusion system (Haemonetics Corp., Braintree, MA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional iv volume administration (37 degrees C) using pressure infusion bags
Number of subjects: 20
Study: 2905134

Group type: EXPERIMENTAL
Intervention: metaclazepam
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 29917226

Group type: EXPERIMENTAL
Intervention: GP2017
Number of subjects: 465

Group type: COMPARATOR
Intervention: ref-ADMB
Number of subjects: 465
Study: 27630501

Group type: EXPERIMENTAL
Intervention: Moxifloxacin-hydroxyapatite composite graft
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hydroxyapatite-placebo gel composite graft
Number of subjects: 15
Study: 26341720

Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise training (RT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Resistance training in combination with nutrient supplementation (RTS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 117
Study: 23754545

Group type: EXPERIMENTAL
Intervention: mesalazine 800 mg twice daily for 10 days every month
Number of subjects: 96

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 96
Study: 20942278

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with nerve block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nerve block
Number of subjects: 90
Study: 18391662

Group type: EXPERIMENTAL
Intervention: Interactive computer-based learning (CBL) courses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text-only courses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive CBL courses
Number of subjects: 0
Study: 16608953

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm for 12 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no inhaled nitric oxide)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (iNO and control)
Number of subjects: 30
Study: 11753136

Group type: EXPERIMENTAL
Intervention: Drugs that modulate the inflammatory response in interstitial cystitis
Number of subjects: 0
Study: 10421236

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [1‐13C]alanine for 3.5 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasogastric tube infusion of [1‐13C]alanine for 3.5 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of IV and NG infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Extraction of enteral alanine
Number of subjects: 12
Study: 7547087

Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg with food
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg with antacid (Maalox)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tenidap sodium 120 mg fasting
Number of subjects: 21
Study: 2179584

Group type: EXPERIMENTAL
Intervention: Orally administered bacterial extract
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 6106500

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30667365

Group type: EXPERIMENTAL
Intervention: Chromosomal instability (CIN) in pancreatic NET
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Chromosomal instability (CIN) in gastrointestinal NET
Number of subjects: 225
Study: 28351374

Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training (WMT) with active personalized coaching and feedback for 8 weeks, 4 days a week, 30 minutes a day.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cogmed Working Memory Training (WMT) without personalized coaching (general non-personalized coaching) for 8 weeks, 4 days a week, 30 minutes a day.
Number of subjects: 52
Study: 25886536

Group type: EXPERIMENTAL
Intervention: Chewing gum postoperatively and standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose solution and standard care
Number of subjects: 0
Study: 23278131

Group type: EXPERIMENTAL
Intervention: Tulathromycin IM
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Doxycycline monotherapy PO
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Doxycycline with rifampin PO
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Azithromycin with rifampin PO
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline IM (placebo)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Azithromycin-rifampin
Number of subjects: 108
Study: 21367495

Group type: EXPERIMENTAL
Intervention: Low glucose intake (2.5 mg kg(‐1) min(‐1))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard glucose intake (5.0 mg kg(‐1) min(‐1))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Standard amino acid intake (1.5 g kg(‐1) day(‐1))
Number of subjects: 17

Group type: COMPARATOR
Intervention: High amino acid intake (3.0 g kg(‐1) day(‐1))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin infusion (80 mU m(‐2) min(‐1))
Number of subjects: 17
Study: 19722799

Group type: EXPERIMENTAL
Intervention: SRP + Xan‐CHX gel treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: SRP treatment
Number of subjects: 98
Study: 17711540

Group type: EXPERIMENTAL
Intervention: 1000 microg fluticasone (Accuhaler) plus 800 microg budesonide (Turbohaler) after induced bronchoconstriction
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1000 microg fluticasone (Accuhaler) plus 800 microg budesonide (Turbohaler) without induced bronchoconstriction
Number of subjects: 20
Study: 15004830

Group type: EXPERIMENTAL
Intervention: 585 nm/0.5 milliseconds
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 595 nm/20 milliseconds
Number of subjects: 15

Group type: COMPARATOR
Intervention: 595 nm/0.5 milliseconds
Number of subjects: 15
Study: 11572292

Group type: EXPERIMENTAL
Intervention: TPH‐Spectrum
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Compoglass
Number of subjects: 52
Study: 9280178

Group type: EXPERIMENTAL
Intervention: Linseed oil (average ALA intake: 5.9 g/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fish oil plus sunflower oil (average EPA + DHA intake: 5.2 g/d)
Number of subjects: 46
Study: 8393884

Group type: EXPERIMENTAL
Intervention: Aspirin (oral)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 13
Study: 3089519

Group type: EXPERIMENTAL
Intervention: Desmopressin (2‐4 micrograms given intramuscularly at 8 pm)
Number of subjects: 5
Study: 31433058

Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 117
Study: 28475159

Group type: EXPERIMENTAL
Intervention: 600,000 IU cholecalciferol (VD group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL group)
Number of subjects: 24
Study: 26003683

Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) 4 × 0.8 g day(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (PLA; soybean oil)
Number of subjects: 80
Study: 23080358

Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intermittent PrEP
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 21649935

Group type: EXPERIMENTAL
Intervention: Referral to a rapid response service that assesses and treats the patient at home
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referral to Emergency Department (ED) via ambulance transfer
Number of subjects: 0
Study: 19344914

Group type: EXPERIMENTAL
Intervention: Montgomery Asberg Depression Rating Scale (MADRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hamilton Depression Rating Scale (HAMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subscales of HAMD
Number of subjects: 0
Study: 16298441

Group type: EXPERIMENTAL
Intervention: Isotonic hydration
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Half‐isotonic hydration
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1383
Study: 15167082

Group type: EXPERIMENTAL
Intervention: CWD‐A (Adolescent Coping With Depression course)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Life skills/tutoring control
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CWD‐A
Number of subjects: 93
Study: 10872953

Group type: EXPERIMENTAL
Intervention: Bone probing measurement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Radiographic bone level (RBL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Probing depth
Number of subjects: 28
Study: 9109757

Group type: EXPERIMENTAL
Intervention: Initial good visual acuity (20/40 or better)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Initial intermediate visual acuity (20/50-20/200)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Initial poor visual acuity (< 20/200)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Eyes with perfusion
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Iris neovascularization (INV) or angle neovascularization (ANV)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Eyes initially categorized as nonperfused or indeterminate
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Eyes initially categorized as perfused
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Neovascular glaucoma
Number of subjects: 725
Study: 8468437

Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg three times daily, adjusted to 300-600 mg/day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day, adjusted to 20-40 mg/day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 122
Study: 2870014

Group type: EXPERIMENTAL
Intervention: 20 mg betaxolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 80 mg nadolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2466712

Group type: EXPERIMENTAL
Intervention: Cadexomer iodine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 67
Study: 31262573

Group type: EXPERIMENTAL
Intervention: Intravenous administration of tramadol 1 mg/kg (group T)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 304
Study: 28341982

Group type: EXPERIMENTAL
Intervention: Short focused cardiac ultrasound scan using a pocket-sized Vscan
Number of subjects: 40

Group type: COMPARATOR
Intervention: No scan
Number of subjects: 40
Study: 25540298

Group type: EXPERIMENTAL
Intervention: Graft volume and median signal intensity (SI) measured via MRI
Number of subjects: 0
Study: 23468056

Group type: COMPARATOR
Intervention: artemether-lumefantrine (AL)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DP)
Number of subjects: 298
Study: 21343767

Group type: EXPERIMENTAL
Intervention: Pipelle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Explora
Number of subjects: 0
Study: 19231778

Group type: EXPERIMENTAL
Intervention: Soft Liner and DuoDERM protection
Number of subjects: 18

Group type: COMPARATOR
Intervention: No cushioning protection
Number of subjects: 18
Study: 16822102

Group type: EXPERIMENTAL
Intervention: Online family problem solving therapy (FPS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Internet resources (IRC)
Number of subjects: 40
Study: 12571159

Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2 mg tablet
Number of subjects: 36
Study: 10685353

Group type: EXPERIMENTAL
Intervention: Emotion-focused therapy (EFT) for couples, 8 weekly sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list (control group), 8-week waiting period
Number of subjects: 40
Study: 9117452

Group type: EXPERIMENTAL
Intervention: Dextrin sulphate (D2S) gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8174967

Group type: EXPERIMENTAL
Intervention: CCK‐33 (0.25 IDU.kg‐1.h‐1) during 8 mmol/l hyperglycaemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CCK‐33 (0.5 IDU.kg‐1.h‐1) during 8 mmol/l hyperglycaemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CCK‐33 (0.25 IDU.kg‐1.h‐1) during 15 mmol/l hyperglycaemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CCK‐33 (0.5 IDU.kg‐1.h‐1) during 15 mmol/l hyperglycaemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CCK‐33 (1.0 IDU.kg‐1.h‐1) during 15 mmol/l hyperglycaemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Basal plasma PP concentrations during hyperglycaemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PP secretion in response to CCK‐33 during hyperglycaemia
Number of subjects: 6
Study: 3956116

Group type: EXPERIMENTAL
Intervention: Gold therapy (Auromyose) in the same dosage schedule as before the study
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (gold in a suspension diluted 1/100)
Number of subjects: 24
Study: 30850143

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise 3 days/week at hospital and 4 days/week at home for 6 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group maintaining original physical activity
Number of subjects: 86
Study: 29208618

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg two times per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (identical to methylphenidate)
Number of subjects: 30
Study: 25398288

Group type: EXPERIMENTAL
Intervention: Lower-extremity amputation (LEA) group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-LEA group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Correlation analyses
Number of subjects: 55
Study: 24576168

Group type: EXPERIMENTAL
Intervention: Fast prehydration regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard prehydration regimen
Number of subjects: 0
Study: 23488361

Group type: EXPERIMENTAL
Intervention: ACNP-led care
Number of subjects: 103

Group type: COMPARATOR
Intervention: Hospitalist-led care
Number of subjects: 103
Study: 19635023

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Vancomycin-gentamicin
Number of subjects: 89
Study: 17577462

Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Delapril 30 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of Manidipine and Delapril
Number of subjects: 40
Study: 15273564

Group type: EXPERIMENTAL
Intervention: High-fidelity model training (live rat vas deferens; n = 21)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-fidelity model training (silicone tubing; n = 19)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Didactic training alone (n = 10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-fidelity model training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-fidelity model training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Didactic training
Number of subjects: 50
Study: 12542882

Group type: EXPERIMENTAL
Intervention: Transurethral vapor resection of the prostate (TUVRP) using the vapor resection loop.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard wire loop TURP.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions were assessed for efficacy using IPSS, Q(max), and residual urine volume.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions were evaluated for complications.
Number of subjects: 100
Study: 9588408

Group type: EXPERIMENTAL
Intervention: RheothRx (poloxamer 188)
Number of subjects: 196
Study: 7832301

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intranasal midazolam
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg intranasal midazolam
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intranasal saline drops (placebo)
Number of subjects: 88
Study: 2212409

Group type: EXPERIMENTAL
Intervention: Regular use of aqueous beclomethasone diproprionate nasal spray (200 micrograms, twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: As required use of aqueous beclomethasone diproprionate nasal spray (100 micrograms, as needed, up to 400 micrograms daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regular use of aqueous beclomethasone diproprionate nasal spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: As required use of aqueous beclomethasone diproprionate nasal spray
Number of subjects: 60
Study: 112457

Group type: EXPERIMENTAL
Intervention: Sodium escinate
Number of subjects: 142

Group type: COMPARATOR
Intervention: Corticosteroid therapy
Number of subjects: 142
Study: 31301293

Group type: EXPERIMENTAL
Intervention: Evolocumab (FOURIER trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bococizumab (SPIRE-1 and SPIRE-2 trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alirocumab (ODYSSEY OUTCOMES trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meta-regression prediction
Number of subjects: 0
Study: 30572069

Group type: EXPERIMENTAL
Intervention: Smaller facemask (35 mm or 42 mm)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard facemask (50 mm)
Number of subjects: 131
Study: 27789268

Group type: EXPERIMENTAL
Intervention: 3-day antibiotic regimen (group A)
Number of subjects: 171

Group type: COMPARATOR
Intervention: 1-day antibiotic regimen (group B)
Number of subjects: 171